Browse the corpus
Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.
3 passages
Therapeutic duplication of paracetamol (e.g., multiple formulations or combination products) is low-value and unsafe. Why: Duplicate paracetamol increases risk of hepatotoxicity due to cumulative dosing without improving analgesia.
Therapeutic duplication of antihistamines (e.g., concurrent oral and topical or multiple oral antihistamines) is low-value. Why: Duplicate antihistamine therapy increases risk of sedation and anticholinergic effects without additional symptom relief.
Concurrent prescription of two or more systemic NSAIDs, or a systemic and topical NSAID, is low-value care. Why: Combining NSAIDs increases the risk of gastrointestinal and renal toxicity without a proven increase in analgesic effect.